JPWO2022226342A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022226342A5 JPWO2022226342A5 JP2023563978A JP2023563978A JPWO2022226342A5 JP WO2022226342 A5 JPWO2022226342 A5 JP WO2022226342A5 JP 2023563978 A JP2023563978 A JP 2023563978A JP 2023563978 A JP2023563978 A JP 2023563978A JP WO2022226342 A5 JPWO2022226342 A5 JP WO2022226342A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragment
- tslp
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims 62
- 150000001413 amino acids Chemical group 0.000 claims 47
- 102000025171 antigen binding proteins Human genes 0.000 claims 31
- 108091000831 antigen binding proteins Proteins 0.000 claims 31
- 108060003951 Immunoglobulin Proteins 0.000 claims 28
- 102000018358 immunoglobulin Human genes 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 20
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 13
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 13
- 229960005261 aspartic acid Drugs 0.000 claims 13
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 12
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 12
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 12
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 12
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 12
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 12
- 230000035772 mutation Effects 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 208000006673 asthma Diseases 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 238000003259 recombinant expression Methods 0.000 claims 4
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims 3
- 238000006317 isomerization reaction Methods 0.000 claims 3
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000000592 Nasal Polyps Diseases 0.000 claims 2
- 102220473585 Putative ankyrin repeat domain-containing protein 26-like protein_S51A_mutation Human genes 0.000 claims 2
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims 2
- 230000006240 deamidation Effects 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 229940072221 immunoglobulins Drugs 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102200050406 rs121918361 Human genes 0.000 claims 2
- 102220039261 rs515726206 Human genes 0.000 claims 2
- 102220269348 rs61747367 Human genes 0.000 claims 2
- 102220057405 rs730881771 Human genes 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 101001008922 Homo sapiens Kallikrein-11 Proteins 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102100027612 Kallikrein-11 Human genes 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 201000001561 eosinophilic gastritis Diseases 0.000 claims 1
- 239000013628 high molecular weight specie Substances 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178915P | 2021-04-23 | 2021-04-23 | |
| US63/178,915 | 2021-04-23 | ||
| PCT/US2022/025999 WO2022226342A2 (en) | 2021-04-23 | 2022-04-22 | Modified anti-tslp antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024516595A JP2024516595A (ja) | 2024-04-16 |
| JP2024516595A5 JP2024516595A5 (https=) | 2025-05-01 |
| JPWO2022226342A5 true JPWO2022226342A5 (https=) | 2025-05-01 |
Family
ID=81597885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563978A Pending JP2024516595A (ja) | 2021-04-23 | 2022-04-22 | 修飾された抗ｔｓｌｐ抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240182558A1 (https=) |
| EP (1) | EP4326762A2 (https=) |
| JP (1) | JP2024516595A (https=) |
| KR (1) | KR20230175245A (https=) |
| CN (1) | CN117177992A (https=) |
| AR (1) | AR125404A1 (https=) |
| AU (1) | AU2022262006A1 (https=) |
| BR (1) | BR112023022041A2 (https=) |
| CA (1) | CA3216700A1 (https=) |
| CL (1) | CL2023003124A1 (https=) |
| IL (1) | IL307439A (https=) |
| MX (1) | MX2023012325A (https=) |
| TW (1) | TW202304980A (https=) |
| WO (1) | WO2022226342A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| WO2024118542A1 (en) * | 2022-11-28 | 2024-06-06 | Takeda Vaccines, Inc. | A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions |
| CN120513100A (zh) * | 2023-01-06 | 2025-08-19 | 江苏恒瑞医药股份有限公司 | 一种tslp抗体治疗哮喘的方法 |
| TW202448501A (zh) | 2023-02-02 | 2024-12-16 | 美商麥迪紐有限責任公司 | 用抗ｔｓｌｐ抗體治療慢性鼻竇炎 |
| CN121443636A (zh) | 2023-05-18 | 2026-01-30 | 免疫医疗有限责任公司 | 用抗tslp抗体治疗皮质类固醇依赖性哮喘 |
| WO2025147632A1 (en) | 2024-01-05 | 2025-07-10 | Medimmune, Llc | Treatment of chronic obstructive pulmonary disease with anti-tslp antibody |
| WO2025221247A1 (en) | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
| WO2025265071A1 (en) * | 2024-06-21 | 2025-12-26 | Paragon Therapeutics, Inc. | Antibodies that bind tslp and methods of use |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| JP4986633B2 (ja) * | 2005-01-12 | 2012-07-25 | 協和発酵キリン株式会社 | 安定化されたヒトＩｇＧ２およびＩｇＧ３抗体 |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| CN101874042B9 (zh) * | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| BR112017019412A2 (pt) * | 2015-03-11 | 2018-05-02 | Glaxosmithkline Ip Dev Ltd | proteínas ligadoras de tslp |
| KR20240070727A (ko) | 2017-04-12 | 2024-05-21 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
| MX2019014615A (es) | 2017-06-08 | 2020-02-07 | Amgen Inc | Dispositivo de administracion de farmacos accionado por par de torsion. |
| SG11202000727SA (en) * | 2017-08-01 | 2020-02-27 | Amgen Inc | Systems and methods for real time preparation of a polypeptide sample for analysis with mass spectrometry |
| CA3079665A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
| ES3042632T3 (en) | 2018-03-13 | 2025-11-24 | Amgen Inc | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| EA202191038A1 (ru) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | Способ платформенной сборки для устройства доставки лекарственного средства |
| MA53912A (fr) | 2018-10-15 | 2022-01-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un mécanisme d'amortissement |
| MA56121A (fr) | 2019-06-05 | 2022-04-13 | Amgen Inc | Procédés d'identification d'attributs de protéines thérapeutiques |
| KR102809618B1 (ko) * | 2019-09-04 | 2025-05-16 | 바이오션, 인코포레이티드 | Tslp에 결합하는 항체 및 이의 용도 |
-
2022
- 2022-04-22 KR KR1020237039566A patent/KR20230175245A/ko active Pending
- 2022-04-22 AU AU2022262006A patent/AU2022262006A1/en active Pending
- 2022-04-22 US US18/287,597 patent/US20240182558A1/en active Pending
- 2022-04-22 AR ARP220101043A patent/AR125404A1/es unknown
- 2022-04-22 WO PCT/US2022/025999 patent/WO2022226342A2/en not_active Ceased
- 2022-04-22 MX MX2023012325A patent/MX2023012325A/es unknown
- 2022-04-22 EP EP22722641.2A patent/EP4326762A2/en active Pending
- 2022-04-22 BR BR112023022041A patent/BR112023022041A2/pt unknown
- 2022-04-22 IL IL307439A patent/IL307439A/en unknown
- 2022-04-22 JP JP2023563978A patent/JP2024516595A/ja active Pending
- 2022-04-22 CN CN202280030029.7A patent/CN117177992A/zh active Pending
- 2022-04-22 TW TW111115432A patent/TW202304980A/zh unknown
- 2022-04-22 CA CA3216700A patent/CA3216700A1/en active Pending
-
2023
- 2023-10-19 CL CL2023003124A patent/CL2023003124A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024150751A5 (https=) | ||
| JP2010538608A5 (https=) | ||
| JP2025016349A5 (https=) | ||
| EP3459968A1 (en) | Novel stable antibody variable domain framework combinations | |
| JP2010246565A5 (https=) | ||
| JP2023515260A (ja) | 抗ヒトインターロイキン－４受容体α抗体及びその調製方法並びに使用 | |
| JP2018516853A5 (https=) | ||
| RU2009128064A (ru) | Антитела к cd44 | |
| CN111615519B (zh) | 结合人il-5的单克隆抗体、其制备方法和用途 | |
| JP2021520825A5 (https=) | ||
| JP2021530244A5 (https=) | ||
| RU2019121106A (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) | |
| JP7698635B2 (ja) | 抗幹細胞因子抗体及びその使用方法 | |
| JP2020513759A5 (https=) | ||
| RU2019123112A (ru) | Анти-il-5 антитела | |
| JP2026048732A5 (https=) | ||
| US20100297135A1 (en) | Epitope for neutralizing antibodies | |
| JP6790307B2 (ja) | 抗ヒトｔｌｒ７抗体 | |
| AU2016232897B2 (en) | Anti-sclerostin antibody, antigen binding fragment and medical use thereof | |
| JPWO2022226342A5 (https=) | ||
| JPWO2019197675A5 (https=) | ||
| JPWO2022111425A5 (https=) | ||
| JP2019518473A5 (https=) | ||
| JP2021518748A5 (https=) | ||
| RU2016117140A (ru) | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |